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Treatment Studies
Clinical trials include
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MD .AN)ERSON study, therapies for
O\NCERCENIER patients with advanced
Making C ancer HistoryN colorectal cancer.
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the treatment of
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Sharing Stories
House Call offers a list
of books written by
people with cancer,
for people with
cancer.

Virtual Colonoscopy
Potential screening
device uses computers to reconstruct
three-dimensional
images of the colon.

MD Anderson
Multidisdplinary Care Improves
Treatment, Enhances Quality of Life
for Patients with Coloredal Cancer
by Mariann Crapanzano

or each patient who
receives a diagnosis
of colorectal cancer,
the struggl,e is a
personal one, encompassing not
only medical treatments but
also psychological and social
adjustments. Optimizing both
the potential far_cure and the
quality of life for these patients
requires the collaborative efforts
of many specialists and an unbroken line of communication.

F

Dr. John Skibber, assodate professor in the Department of Surgi,cal Oncology, Dr. James
Abbruzzese, professor and chairman of the Department of Gastrointestinal Medical
Oncology, and Dr. Christopher Crane, assistant professor in the Department of Radiation
Oncology (l,eft to right), examine computed tomography scans of a patient's colon.

"It's not just what the doctors do
in terms of the surgery, radiation
therapy, and chemotherapy," said
John M. Skibber, M.D ., an associate
professor in the Department of
Surgical Oncology at The University
of Texas M. D. Anderson Cancer
Center. "It's the whole multidisciplinary approach that helps to
achieve the optimal outcome."

(Continued on next page)

Multidisciplinary Care Improves Quality of Life
(Continued from page 1)

Sphincter-preserving surgery
ne result of this approach is
an increase in th e number
of patients with rectal cancer
who undergo sphincter-preserving
surgery. Patients with locally advanced cancer in th e lower part of
the rectum have in th e past been
treated with an abdominoperineal
resection and a permanent colostomy. With state-of-the-art staging
and surgical techniques, Dr. Skibber
said, many of these patients can
now undergo a proctectomy and
coloanal anastomosis. In this
procedure, the rectum and mesorectum are removed, using intraoperative analysis to ensure tumor-free
margins, and the descending and
transverse colon is freed and then
connected by anastomosis to the
anal canal, thereby preserving the
patient's sphincter and eliminating
the need for a colostomy.
"We are strongly interested in
sphincter-preserving techniques,"
said Dr. Skibber, "but not at the cost
of a poor cancer operation. And
that's a delicate judgment."
The determination of whether a
patient is a candidate for sphincterpreserving surgery depends largely
upon the precise and accurate
·
staging of the disease. This staging is
ideally a joint effort by pathologists,
who evaluate tissue samples that are
obtained preoperatively, and gastroenterologists and radiologists, who
perform endoscopic and imaging
studies in conjunction with the
surgeon.

0

Treatment planning
and preoperative therapy

E

ndorectal ultrasound and
conventional staging modalities, such as computed tomography (CT) and magnetic resonance
imaging (MRI), help determine the
involvement of structures surrounding the rectum. Sandeep Lahoti,
M.D. , an assistant professor in the
Department of Gastrointestinal
2 / MD Anderson OncoLog

" ... other than the presence of
metastatic disease, the depth of
penetration is the primary prognostic
factor in determining how the patient
is going to do."
- John M. Skibber, M.D.,
associate professor, Department of Surgical Oncology

by providing early treatment of
Medicine and Nutrition, and others
micrometastatic d isease, said
at M. D. Anderson also routinely use
James L. Abbruzzese, M.D.,
endorectal ultrasound in cases of
rectal cancer to evaluate the different professor and chairman of the
Department of Gastrointestinal
layers of the rectal wall and to
Medical Oncology.
determine how deeply the tumor
According to Dr. Abbruzzese,
invades the wall.
improving the effectiveness of
According to Dr. Lahoti, if
chemotherapy fo r colorectal cancer
endorectal ultrasound, CT, or MRI
shows that the tumor extends beyond is an ongoing process. "Medical
oncologists collaborate with surgeons
the inner wall of the rectum, preopand radiation oncologists on neoerative chemotherapy and radiation
adjuvant studies to develop new .
therapy may be administered in an
therapies for patients who have
attempt to downstage the tumor, in
more advanced cancers," he said.
some cases making an unresectable
Dr.Janjan and Christopher H.
tumor resectable.
Crane, M.D., an assistant professor in
'That's important because, other
the Department of Radiation Oncolthan the presence of metastatic
ogy, administer radiation therapy to
disease, the depth of penetration
patients with colorectal cancer. In an
is the primary prognostic factor in
determining how the patient is going effort to improve results over those
obtained with standard radiation
to do," said Dr. Skibber. "By the use
therapy, Drs. Janjan and Crane were
of endorectal u ltrasound, we can
instrumental in initiating a concomiidentify patients who have high-risk
tant boost radiation protocol in
cancers before we operate on them
which increased d oses of radiation
and therefore offer them radiation
are delivered to the site of the
and chemotherapy before surgery
primary tumor during preoperative
and give them the benefit of possibly
chemoradiotherapy.
having their sphincters preserved."
"Preliminary analysis of this phase
In a recent study led by Nora A
II
protocol
indicates that concomiJanjan, M.D., a professor in the Department of Radiation Oncology, preopera- tant boost therapy provides an
tive chemoradiation allowed sphincter- increase in tumor downstaging
and sphincter preservation with
preserving surgery to be performed in
no apparent increase in toxicity,"
40% of patients who otherwise would
said Dr. Crane.
have had a colostomy.
Dr. Crane and othe rs at M. D.
Preoperative radiation therapy
Anderson are investigating the use
has the added benefit of reducing
of three-dimensional conformal
the recurrence rate in patients with
locally advanced rectal cancer, said
boost radiation therapy, a delivery
technique that is more accurate and
Dr.Janjan. And neoadjuvant chemoallows the site of the primary tumor
therapy may benefit these patients
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Sharing Personal Stories:
Books Written by People with Cancer
hen you or someone close to you has cancer, support
can come from many sources-family, friends,
health professionals, clergy-but have you ever
considered turning to a good book for help and
comfort? Below is a list of personal stories-written by people
who have experienced cancer-that offer inspiration, hope,
and acceptance to those who read them.

That's Unacceptable
' by Rebecca L. Libutti
First treated for a sinus infection,
Rebecca L. Libutti later discovered
that the cause of her debilitating
headaches was a rare brain tumor
called glioblastoma multifor m e .
Libutti tells an inspiring story of
courage and sur vival in the face of
a potentially ter minal disease.

� It's Always Something
� lJy Gilda Radner
Survivor
; r, Gilda Radner, best known for
• · � E;;, lJy Laura Landro
her days as a young comedienne
1
�
A Wall Street Journal reporter and
on Saturday Night Live, wrote this
editor uses he r journalistic training
book
after her ovarian cancer was
to research and understand her
diagno
sed in the 1980s . Ke eping her
diagnosis of chronic myelogenous
sense of humor throughout, Radner
leukemia. As Laura Landro tells her
shar es h er perspec tive on
story, she also teaches reader s how to
make informed decisions about their life and cancer.
Books by Writers

own treatment.

. __ .,, Dancing at the Edge of Life:
A Memoir by Gal,e Warner
'" Poet and writer Gale Warner
takes us on her 13-month journey
with non-Hodgkin' s lymphoma as
she re cords her experiences in a
journal and comes to terms with
her disease and her own mortality.

�?

/ A Whole New Life
lJy R.eynol,d,s Price
· i r:, Southern novelist, poet, and
writer Reynolds Pr ice recounts
his experience with cancer of the
spinal cord, which has left him
partially paralyzed. His tale begins
before his initial diagnosis in 1984
and takes us through his inspirational
recovery with the help of medicine,
religion, and personal strength.

· · i /5.

New York Times Bestsellers

,,

and Notable Books

Books by Doctors

H aling Lessons by Sidney J
, ,/ �
?'"( Wznawer and Nick Taylor
In this book, a prominent cancer
specialist must face his own wife ' s
metastatic stomach cancer. It is the
story of a doctor seeing cancer from
a new perspective a nd of a woman
desperately searching for a cure
for her life-threatening illness.
Prostate Cancer: A Doctor's
Personal Triumph
lJy Saralee Fine and Robert Fine
Dr. and Mrs . Robert Fine had
been together for 40 years when
Dr. Fine was told he had prostate
cance r. This book recounts the
couple's search for the appropriate
treatment and includes a wealth of
re sources for acces s ing accurate
medical information.

Other Suggested Titles
.
.
· _ / . Autobiography of a Face
No �un� to Die
_
, � .;::;_
l7y Lucy Grealy
·
Lzz
. t t. _ by_ _ Tzlb':'1s
'" Lucy Grealy's bone cancer was '
Liz Til?ens, for�er editor-in-:hief
diagnosed before her 10th birthday
of Harper s Bazaar, g ives us a behmdand cured only after a third of her
th
e-�cenes loo� at the world of
jaw was removed. This is her memoir
shion maga7:me a s he displays
fa
� �
of living with disfigurement, dealing
fi�rce de �ermmation m her battle
,
s
r
with rejection from her pee and
Wi th ovanan cancer.
striving for acceptance .

?£,;

Cancer...There's Hope
by_ Richard and Annette Bloch
Richar d Bloch, co-founder of the
tax return preparation company H&R
Block, Inc., tells his no-nonsense stor y
of surviving lung cancer in the 1970s .
The Blochs also emphasize the
importance of having a positive
mental attitude and obtaining the
best medical care available. Copies
of this title and other books by the
same authors are available free
from the R. A. Bloch Cancer
Foundation (www.blochcancer.org)
at 1-800-433-0464.
Most of the titles listed above, as well
as many, many more, have been recom
mended lJy and are available through
The Learning Center at The University
of Texas M. D. Anderson Cancer Center.
A list of books for chil,d,ren can be found
on The University of Pennsylvania
Cancer Center Web site, OncoLink
(http:IIcancer. med. upenn. edu/).
Additional titles can be found l7y
calling the Cancer Information Service
at 1-800-4-CANCER •

For more information, contact
your physician or contact the
M. D. Anderson Information Line:
({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 in Houston
and outside the United States .
September 2000
©2000 The Universitry oJTexas
M. D. Anderson Cancer Center
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PROTOCOLS - - + - - - -

Clinical Trials for Coloredal Cancer
Clinical trials in progress at The University of Texas M. 0. Anderson Cancer Center
include the following for patients with
colorectal cancer.
• Phase 11 study of radiofrequency
ablation of colorectal cancer liver
metastases combined with postablation
hepatic arterial infusion of floxuridine
alternating with 5-fluorouracil (1098035) . Physician: Lee Ellis, M.D.
This study is designed for patients
with colorectal cancer who have
metastatic disease only in the liver that
has not responded to systemic chemotherapy. Patients must have no more
than six tumors and no tumor larger
than 4 cm in its greatest dimension.
Participants must also have a life
expectancy of at least 16 weeks. Patients
are excluded if they have had prior liver
irradiation or if they have gross ascites,
evidence of cirrhosis, or active duodenal
or gastric ulcers.
• A phase 1-11 study of escalating doses of
SU5416 (NSC 696819) in combination
with irinotecan (CPT-11 ) in patients with
advanced colorectal carcinoma (1099243) . Physician: Paulo Hoff, M.D.
Patients with measurable adenocarcinoma of the colon or rectum in a locally
advanced or metastatic stage are eligible.
Patients must also have adequate hepatic
function and have recovered from any
prior surgery or rad iation therapy. Patients
may have received prior chemotherapy
but are excluded if they have previously

to receive a larger total dose of
radiation while normal tissue is
spared.

Treatment of metastatic disease

N

eoadjuvan t and adjuvan t
therapies in crease response
rates and even help cure
many patients, but other patie n ts
must figh t metastatic disease, espe-

received SU5416, CPT-11,
or any topoisomerase I inhibitor.
• Pilot study of graft-versus-tumor
induction: High-dose chemotherapy
with allogeneic peripheral blood stem
cell transplantation for patients with
metastatic colon cancer (OM95-106).
Physician: Richard Champlin, M.D.
The colon is a target for graft-versushost reactions that occur after stem cell
transplantation, so allogeneic hematopoietic transplants may confer an
immune-mediated graft-versus-tumor
effect in colon cancer. Patients 18 to
55 years old who have histologically
confirmed metastatic colon carcinoma,
have received more than one treatment
regimen, and have a related HLAidentical donor are eligible. Patients
must also have adequate cardiac and
pulmonary function. Exclusion criteria
include evidence of hepatitis or cirrhosis, HIV, pregnancy, and central nervous
system metastases.

recurrence and may have concurrent
distant metastases but no pelvic
malignancies other than rectal
carcinoma. Those who have had
documented pelvic pain syndrome or
chronic constipation prior to cancer
diagnosis are excluded.
• A phase II chemoprevention study of
calcium and aspirin in subjects with
previously resected adenomatous polyps
of the colon (CAPT Study) (OM93-129) .
Physician: Frank A. Sinicrope, M.D.
This study is designed for patients 40
to 80 years old who have had a colon
adenoma removed within the last five years
and who have at least half of their colon
intact. Participants must also have no
family history of adenomatous polyposis or
hereditary nonpolyposis colon cancer and
no personal history of gastrointestinal
ulcers or bleeding or adverse reactions to
aspirin. Patients who have used calcium
supplementation at doses greater than 500
mg per day in the four months prior to
enrollment or who have a history of pelvic
irradiation are excluded. •

• Analysis of patients with locally recurrent rectal carcinoma: Prospective
assessment of quality of life, outcome of
therapy, and management of pain (1097106). Physician: John M. Skibber, M.D.
This study is designed for patients
with locally recurrent rectal carcinoma
who either speak and understand
English or have an interpreter available
to answer questions. Participants must
have had a period of at least three
months between initial treatment and

about these clinical
trials, physicians or patients may call
the M. D. Anderson Information Line.
Those within the United States should
call (800) 392-1 611; those in Houston
or outside the United States should call
(713) 792-6161. VisittheM. D.Anderson Cancer Center clinical trials Web site
at http://www. clinicaltrials.orgfor a
broader listing of treatment research
protocols.

cially in the liver, said Steven A.
Curley, M.D ., a p rofessor in the
Departmen t of Surgical O ncology.
According to Dr. Curley, som e
patie n ts wi th liver m etastases may be
candidates for surgical resection or
radiofreque n cy ablation-a procedure in which the liver metastases are
destroyed with an electrical curre n t
delivered directly to the tumor
through a n eedle electrod e-with o r

witho u t placem ent of a he patic artery
pump fo r chem othe ra py.
"There are a lo t of physician s
who, when they see a p atien t with
advan ced disease or m etastatic
disease, say there's not a lot that can
be d one. While tl1at m ay be true in
some cases, it's not tru e for ever ybody," Dr. Curley said. "We do have
a ver y aggressive and p romising
(Continued on page 4)

FOR MORE INFORMATION
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Multidisciplinary Care Improves Quality of Life
( Continued from page 3)

multidisciplinary management
program to treat liver metastases
from colorectal cancer."

Management of bowel function

I

n addition to fighting the cancer,
the multidisciplinary team helps
patients manage bowel dysfunction that may result from some
treatments for colorectal cancer.
Enterostomal therapy nurses work
with patients who have undergone a
colostomy, helping them learn to
care for their stomas and to address
the psychological and social issues
left in the wake of the procedure.
Annette K. Bisanz, an advanced
practice nurse, led the development
of practice guidelines and patient
education materials for bowel management after colorectal surgery.
Bisanz and others provide rehabilitative therapy for patients with bowel
dysfunction, particularly those who
have had their rectums removed.
Many of these patients experience
very frequent bowel movements,
which often can be managed with
diet, appropriate amounts of medicinal fiber, fluid, and medication. With
rehabilitative therapy, patients whose
bowel functions are profoundly
disrupted following surgery can
return to very active lives, agreed
Dr. Skibber and Bisanz.

Palliative care
espite advances in multimodality treatments and
in staging and surgical
techniques for colorectal cancer,
some patients are faced with
unresectable or extensive metastatic
disease that is incurable. Eduardo
Bruera, M.D., a professor and chairman of the Department of Symptom
Control and Palliative Care, said
that advanced, incurable colorectal
cancer presents a number of challenges, primarily pain (often from
liver metastases or retroperitoneal
disease), fatigue, and cachexia. In
addition, these patients and their

D

4 / MD Anderson OncoLog

families must confront issues regarding the patient's end-of-life care.
In most cases of incurable disease,
pain can be well controlled with oral
medications, said Dr. Bruera, something that was not possible as recently
as 10 or 15 years ago . In patients for
whom oral medication is ineffective,
intravenous medication or, occasionally, a nerve block (performed by an
anesthesiologist) may provide palliation. Also, the psychological, social,
and informational needs of the
patient are addressed in a session
with various specialists, ranging from
physical and occupational therapists
to a pastoral care counselor, Dr.
Bruera said.

Screening and prevention

A

cutely aware of the effects
of advanced disease, other
specialists work toward
preventing colorectal cancer in both
high-risk and general populations.
In a study published in the June 29,
2000, issue of The New England Journal
ofMedici,ne, researchers at M. D.
Anderson and several other institutions
showed that the drug celecoxib
significantly reduced the number of
colorectal polyps, or adenomas, in
patients with familial adenomatous
polyposis (FAP). FAP causes the
formation of innumerable polypsprecursors to colorectal cancer-inside
the bowel and places patients at very
high risk for colon cancer. Bernard
Levin, M.D. , a professor in the Department of Gastrointestinal Medical
Oncology and an investigator in the
celecoxib study, said that further
studies will help delineate the usefulness of the drug in cancer prevention.
In one such study, Frank A.
Sinicrope, M .D. , an associate professor in the Department of Gastrointestinal Medicine and Nutrition, and
others at M. D. Anderson are evaluating whether celecoxib alone and in
combination with difluorome thylornithine (DFMO) can cause existing
polyps to regress and prevent the
formation of n ew polyps in patients

with FAP. Dr. Sinicrope said that
celecoxib has also been slated for
a trial to determine whether it can
prevent the formation of polyps in
children and adolescents who have
the genetic mutation associated
with FAP.
Celecoxib is also administered to
control the growth of polyps in some
patients with FAP who wish to delay a
colectomy. "The drug is not a substitute for surgical resection [in these
patients]," said Dr. Sinicrope, "and
its utility in the management of
patients with FAP h as yet to be
defined."
Because colon cancer generally
develops slowly fro m one or more
benign adenomas, said Dr. Levin,
regular screening to detect abnormal
changes in the intestine can help to
reduce the incidence of cancer. Dr.
Levin, who serves as vice president
for cancer prevention, and others at
M. D. Anderson are also investigating, in multi-institutional studies,
methods to detect changes in stool
that occur as colon cancer develops,
such as genetic mutations in cancer
cells that are shed into the stool.
According to Dr. Levin, these methods appear to have great promise as
screening tools. In the meantime,
however, he urges physician s and
patients to use available techniquesthe fecal occult blood test, flexible
sigmoidoscopy, double-con trast
barium enema, and colonoscopyto detect precursors to colorectal
cancer and early-stage cancer and,
ultimately, to prevent deaths from
colorectal cancer. •
contact Dr. Skibber
at (713) 792-5165, Dr. Lahoti at (713)
792-2828, Dr. Janjan at (713) 7923432, Dr. Abbruzzese at (713) 792-2828,
Dr. Crane at (713) 792-0782, Dr. Curley
at (713) 794-4957, Annette Bisanz at
(713) 792-6012, Dr. Bruera at (713)
792-6084, Dr. Levin at (713) 792-3900,
or Dr. Sinicrope at (713) 792-2828.
FoR MORE INFORMATION,

I See page S for related story.

Virtual Colonoscopy a Potential Screening Reality
by Mariann Crapanzano

T

he image on the computer
screen simulates the inside of
a patient's colon, depicting
haustral folds with alternating waves
of shadow and light. It can be a still
image or a fluid one, navigating
through the straightaways and turns
of the colon in what is known as a
"fly-through sequence." Along the
way, any intraluminal polyp or cancer
that is detected appears as a three
dimensional rise in the bowel wall.
These irregularities in the wall
are real, but the reality-based images
are created with virtual colonoscopy,
a technique that uses high-speed
helical computed tomography (CT)
of a patient's abdomen and pelvis
to acquire axial scans, which can be
reformatted into coronal and sagittal
images as well as reconstructed into
three-dimensional images of the
colonic lumen. Still in its investiga
tional stages, virtual colonoscopy
appears to have promise as a screening
device for adenomatous polyps and
colon cancer.
Professor Ronelle A. DuBrow,
M.D., and Assistant Professor Revathy
B. Iyer, M.D., both of the Department
of Diagnostic Radiology at The
University of Texas M. D. Anderson
Cancer Center, are investigators in
a multi-institutional trial to evaluate
the use of virtual colonoscopy as a
screening tool for average- or moder
ate-risk patients in a clinical setting.
According to Dr. Iyer, each of the
more than 1,000 patients in the study
will undergo both a virtual and a
conventional colonoscopy. The
results of both tests will be compared,
and the accuracy of the virtual colon
oscopy will be determined by how
closely its results match those of the
proven conventional colonoscopy. A
major focus of the study is determin
ing the sensitivity of virtual colon
oscopy for detecting colonic lesions,
particularly those larger than 5 or 6
mm, which are at highest risk for
being or developing into colon
cancer, said Dr. Iyer.
During virtual colonoscopy, the
bowel is distended by insufflating it

with carbon dioxide or air.
The CT scan then takes
about 25 seconds, said Dr.
Iyer. A radiologist interprets
both the two- and three
dimensional images, which
are preserved and can be
reviewed by more than one
person. Excluding the time
needed to prepare the colon
with laxative agents, the
entire process can take less
than an hour.
Because an endoscope is
l'.11.l
not used during the proce
Endoluminal views from virtual colonoscopy and
dure, virtual colonoscopy is
computed tomography (inset) show a small polyp
less invasive than conven
(arrow).
tional colonoscopy, and the
Despite this, Dr. Lahoti said that
patient does not have to be sedated,
virtual colonoscopy "will probably pl ay
said Dr. DuBrow. Its potential as a
screening tool, she said, is "to exclude a big role in screening" in the future.
Dr. DuBrow agrees. "The procedure
polyps and cancers in asymptomatic
has tremendous potential as a screen
patients, who will then not need to
ing tool," she said. "If the test proves
undergo conventional colonoscopy."
Like conventional colonoscopy, virtual to be sensitive and specific, it could
profoundly affect screening for the
colonoscopy provides images of the
average-risk population over 50."
entire colon, something that two
This is important because
methods currently being used for
age-appropriate, population-wide
colon cancer screening-the fecal
colorectal cancer screening could
occult blood test and flexible sigmoi
doscopy-cannot do.
help to dramatically reduce the
morbidity and mortality from colon
However, the procedure has
cancer. According to Bernard Levin,
some limitations. The sensitivity and
M.D., professor of medicine in
specificity of virtual colonoscopy as
the Department of Clinical Cancer
a population-wide screening tool
Prevention and vice president for
have yet to be determined. Virtual
colonoscopy does not allow direct
cancer prevention, colon cancer is
unique in that it generally begins
endoscopic visualization of the
with a slow-growing, benign ad
intestinal lumen as conventional
enoma. Colorectal polyps that are
colonoscopy does and cannot always
precursors to cancer can be detected
distinguish residual fecal material in
through screening and then removed
the colon. And unlike conventional
colonoscopy, said Dr. Iyer, abnormali during a conventional colonoscopic
examination, thus preventing the
ties that are detected on virtual
development and growth of cancer.
colonoscopy cannot be biopsied or
removed during the procedure.
Although the procedure has not
yet been proven, Drs. DuBrow and
"I think virtual colonoscopy will
Iyer believe that virtual colonoscopy
be useful as a diagnostic tool, but
obviously, it can't be therapeutic,"
has the potential to one day join
available screening methods in
said Sandeep Lahoti, M.D., an assis
helping to reduce the number of
tant professor in the Department
of Gastrointestinal Medicine and
colorectal cancer deaths. •
Nutrition, "so if you do see a polyp or
mass, the patient would have to be
FoR MORE INFORMATION, contact Dr: DuBrow
referred for conventional colon
at (713) 794-4539, Dr: Iyer at (713) 792oscopy. The big question is going to
5043, Dr: Lahoti at (713) 792-2828, or
be whether this is cost-effective."
Dr: Levin at (713) 792-3900.
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Cervical Cancer
Prevention: Could
Spedroscopy Steal
the Spot"light"?
by Kerry L. Wright

woman visits her
loca~ gynecolo!fst for
routine screening
and lYy the time she
leaves has received a diagnosis
of cervical cancer and is ready
to begin treatment. Fact or
fiction? Fiction-for now, but
this scenario could soon become
reality if a new FDA-approved
cervical cancer detection device
proves effective in an ongoing
clinical trial.

A

The new device, based on fluorescence and reflectance spectroscopy,
will be evaluated for clinical performance, patient satisfaction, and costeffectiveness in 1,800 women in
British Columbia, Canada, and three
Houston locations, including The
University of Texas M. D. Anderson
Cancer Center. If results prove
promising, the spectroscope could
one day join, or possibly replace,
the Pap smear as the standard
screening tool for cervical cancer.
"A patient has a Pap smear. They
wait two weeks for the results, and
they come in for a colposcopy and
a biopsy. They wait two more weeks
for those results, and then they get
treated," explained Michele Follen,
M.D., Ph.D., recipient of the Boone
Pickens Distinguished Professorship
for Early Cancer Prevention and
a professor in the Department
of Gynecologic Oncology at M. D.
Anderson. "If you could use colposcopy and spectroscopy at the first
visit and make a diagnosis with good
reliability, then you could treat them
at visit one instead of doing a screening Pap smear and colposcopically
6 / MD Anderson OncoLog

directed biopsies,"
said Dr. Follen,
who is the principal
investigator of the
Houston portion
Trey Kell, a database coordinator, and Karen Rabel, an
of the trial.
advanced practice nurse in the Department of necologi.c
The device is
Oncology, view data coll.ected during a cervical creening
being evaluated
examination
u ing a spectro cerpy probe.
in two separate
experiments: one
ity of~
'Jho
th pro! 1
tests it in a screening mode and the
and
·
th
duate
other in a diagnostic mode (in the
ch
stitu 1
colposcopy clinic). Each experiment
of
aln . th
is stratified for patient age and
b
nd
menstrual status. The flat probe i
prec
and
painlessly inserted into a patient's
n ck, mou
I al 11 ~
cervix, where it shines light and
one
1sccl 1!
records fluorescence and reflectance
t c
Th e
data that are sent back to a computer
and
for analysis.
The fluorescence component
co
th e
detects and allows evaluation of
n
tw
changes in chemical signals and th
it'i
c cen1x
redox potential of the tissue, which
are predictors of cancer.
\ 1l)'
b
, pecili1 ity
comp
lpo.,._
co
itics of

00%

Michele Follen,
M.D., Ph.D.

Rebecca RichardsKortum, Ph.D.

"The reflectance looks at light as
it hits tissue and comes back, and it's
really looking at how crumpled the
chromatin is in the cells," said Dr.
Follen. The more crumpled the
chromatin, the more the light
scatters and the less it reflects back.
The more light the cervix reflects,
the more likely it is to be cancerous.
Dr. Follen has been collaborating
for nearly 10 years with Rebecca
Richards-Kortum, Ph.D., an electrical
engineering professor at The Univer-
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ha shown that if the r earch-leve l
device were u ed in conjunction
with colposcopy in the nit d rates
toda , it could a e 625 million a
year in unnece ar tests or treatments. The pectro cope can be
made for as little a 3,500, making
its use feasible not on! in the United
States but also in the Third World ,
where invasive cervical cancer rates
are much higher than the 13,000
new case reported each ear in
this country. •
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Treating Cancer with a Team Approach
David L. Callender, M.D.
Senior Vice President and
Chief Medical Officer
Fueled by research ,
new discoveries
continue to increase our understanding of cancer
and improve our
treatment methods-from standard
therapies such as
chemotherapy,
radiotherapy, and
surgery to new approaches such as
immunotherapy and gene therapy.
Similarly, the tools of the pathologist
and diagnostic imaging specialist are
improving, allowing for earlier and
more complete detection and diagnosis.
Supportive care interventions for patients with cancer are also getting better
and have become a major focus of
cancer treatment centers today.
As our methods improve, however,
the complexity of treatment grows. To
achieve the best outcome, interventions
must be carefully timed and monitored,
and caregivers from all of the involved
disciplines must communicate well and
work together closely. This type of communication and cooperation among
caregivers and with their patients is
greatly enhanced when all are together
at one site. The University of Texas M. D.
Anderson Cancer Center helped pioneer
the concept of multidisciplinary care
under one roof over 50 years ago, and
multidisciplinary care is now the principal
model for cance r care at comprehensive
8 I MD Anderson OncoLog

cancer centers across the nited tate .
The benefits of effective multidi iplinary care are (1) a more com pl t
evaluation , (2) precise diagno is, (3)
individualized treatment planning, (4)
well-coordinated treatment delivery,
and (5) appropriate and conveni nt
posttreatment management.
At M. D. Anderson, we continue
to refine our methods of providing
multidisciplinary care to our patients.
We now bring together physician ,
nurses, and support personnel in
Multidisciplinary Care Center (MCC ) ,
which focus on the patient and hi or
her particular cancer and associated
problems. Team members evaluate the
patient, perform sophisticated diagno tic testing in close consultation with
pathologists and imaging peciali ts,
and craft an individualized treatment
plan . The MCC team then monitors
all subsequent care of the patient.
While patients may receive treatment in different areas of the institution, the MCC is their home ba e for
contact with their caregivers. As a
result, the MCC team members and
their patients get to know each other
very well, and these relationships allow
physicians to better serve the specific
needs of their patients.
We believe disease-focused MCCs
that allow for improved communication between the patient and the
caregiver team and promote coordination and cooperation between specialists are even more necessary as new
discoveries and new technologies
improve our ability to treat patients
with cancer.
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About These Clinical
Practice Guidelines
This guideline may assist in the
diagnostic evaluation of patients with
clinical symptoms or positive screening
tests (if such testing exists). The clinician
is expected to use independent medical
judgment in the context of individual
clinical circumstances to determine any
patient's care.
M. D. Anderson Cancer Center's
Practice Guidelines are continually
updated as new information becomes
available and are being expanded to
include the entire spectrum of cancer
management. New guidelines for screening
and diagnosis are currently under
development. Access the most current
version of all M . D. Anderson Practice
Guidelines from M. D. Anderson's Home
Page at http://www.mdanderson.org.
Continuing Medical Education:
An expanded version of these
materials with CME category 1
credit is available on the Internet.
Access Practice Guidelines from
M. D. Anderson's Home Page at
http://www.mdanderson.org.
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DISCUSSION:
Malignant Melanoma
Scape of This Guideline

Jeffrey Lee, M.D.
Medical Di rector,
Melano~a and Skin
Center J
Associate P[ofessor of
Surgical pncology
Departme9t of
Surgical ncology

This guideline begins with a
diagnosis of malignant melanoma
confirmed by pathologic evaluation
and ~ddresses staging, treatment, and
follow-up care in this clinical setting.

Merrick Ross, M.D.
Chief, Melinoma/
Sarcoma l~ervice
Professor iof Surgical
Oncolo
Departme t of
Surgical pncology

Overview
Most melanomas (90%) present
as cutaneous lesions discovered by
self-examination or physician examination, but noncutaneous lesions may
also occur in the pigmented cells
of the retina or in the mucosa
of the oral cavity, nasopharynx,
vagina, vulva, or anal canal. The
noncutaneous lesions tend to be
more advanced when detected.
Melanomas characteristically have
two distinct growth phases; the first is
a radial growth phase characterized
by tumor cells in the epidermis and
papillary epidermis, and then a
vertical growth phase occurs in which
tumor cells begin to penetrate deeper
layers of the skin. The propensity for
metastasis is characteristically low

f

Gunar Zaga~s, M.D.
Associate Medical
Directo;J Genitouri~ ·
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Synapsis & Highlights

during the radial growth phase but
rises significantly during vertical
growth. Melanomas tend to metastasize through regional lymph atics
to adjacent and distant skin sites
(in-transit metastases) and to regional
lymph nodes and also hematogenously to distant sites.
Evaluation & Workup

Biopsy and microstaging
The first step in the evaluation
of a suspicious lesion is biopsy for
definitive diagnosis and microstaging.
Tumor thickness, as measured by
Breslow's thickness scale, and depth
of penetration, classified by Clark's
level, are critical parameters; therefore, full-th ickness biopsy is preferred.
Excisional, directed incisional, or
punch biopsies are all accep table.
Shave or curette biopsies are not
appropriate for suspected m elanoma,
nor are cryosurgery or electrodesiccation techniques, as these methods
do not allow for path ologic analysis
of tumor depth and margins. Wide
excision of the lesion should not be
attempted at time of biopsy, as this
may compromise later lymphatic
mapping stu dies. Specimens sh ould
be analyzed by serial section s rath er
than frozen sections, and this work
should be performed by a path ologist
experien ced in analysis of skin
(Continued on next page)

Melanoma
INITIAL
EVALUATION

Q

CLINICAL
PRESENTATION

WORKUP

11-----1~.il

TREATMENT

No additional j
workup

►

(

FOLLOW-UP

__
Localexc1s1on, O.S-1 cm margin• )
.

►I

J
~·===========--:-----.

t-l

I
<1.0 mm and Clark IV or
ulcerated or regression

Local excision, 1 cm margin"

for 4 yr, then annually

Physical exam, skin survey,
CXR, LOH every 4 mo for
2 yr; every 6 mo for 2 yr;
then annually

NOMO
Consider LM/SLND; or ELND (consider parotidectomy if head/neck

>1.0 mm, any Clark
NOMO

I LOH, CXR

Local recurrence,
any Clark

NOMO
Primary
medical
exam
Pathology
review

AnyT
N2 (in-transit)

►1----~.i1

CBC, LOH, CXR ,
CT of abdomen
and pelvis if
inguinal nodes
involved; CT of

1 - - - ~ head and neck

MO

if cervical nodes
involved

MO

AnyT
AnyN
M1

1------

primary tumor) ; lymphoscintigraphy for ambiguous lymphatic drainage
Local excision , 2 cm margin"
Consider radiotherapy/dental consult if head/neck primary tumor

Consider LM/SLND ; lymphoscintigraphy for
.....____._.,. ambiguous lymphatic drainage
Local excision, 2 cm margin*
Consider radiotherapy if locally recurrent

negative

Local excision

1------+1

Consider isolated hyperthermic limb perfusion
Consider clinical trial, interteron or IA chemotherapy

r----------1

LND (consider parotidectomy if head/neck primary tumor)
.....____._.,. Local excision if primary tumor untreated
Consider clinical trial or interferon
Consider radiotherapy (and dental consult if head/neck
primary tumor) for high risk

AnyT
N1 •2 (nodal)

CBC, differential,
platelets, alkaline
phosphatase,
LOH, creatinine,
total bilirubin,
albumin, SGPT,

Non
·CNS

ELND = Elective lymph node dissection
LM = Lymphatic mapping
SLNO = Selective lymph node dissection
based on results of sentinel lymph node evaluation

LMO

........__

Physical exam, skin survey,
CBC, LOH, CXR , every

3 mo for 2 yr; every 6 mo
for 3 yr; then annually;

I

•

I CT of abdomen and pelvis ,
if inguinal nodes involved,
every 6 mo for 2 yr

Clinical trial of systemic chemotherapy, e.g., CDDPNelban/DTIC/interleukin-2/interferon
Consider locoregional therapy for limited and/or symptomatic disease:
a) Surgery
b) Radiotherapy
c) Arterial infusion therapy
Individualize:
- Surgery if resectable
- Stereotactic radiotherapy for deep lesions
- Whole brain radiotherapy
- Clinical trial (systemic treatment)

CXR , CT of chest
and abdomen ,
MRI brain , bone
scan if
symptomatic

LMD = Leptomeningeal disease

Physical exam, skin survey,
every6mofor4yr, then
annually

l----------------;►
~1 CXR,
Physical
exam
, skin
survey ,
LOH,
every
6 mo

Consider LM/SLND; lymphoscintigraphy
for ambiguous lymphatic drainage
Local excision, 1 cm margin*

LOH, CXR

Treatment

Individualize follow-up to

I

• 1 patient based on tumor
distribution

Individualize:
- lnterleukin-2 via Omaya or clinical trial
- Palliative radiotherapy

• Consider function and cosmesis

Ver:Compass/2/31# 1

This practice guideline was deve!,o,ped in a collaborative effort between the physicians and nurses at The University of Texas M. D. Anderson Cancer Center and the
National Comprehensive Can cer N etwork. The core deve!,o,pment team at M. D. Anderson working on this practice guideline inclu ded Dr. Kie Kian A ng, Dr. Omar Eton,
Dr. Sharon Hymes, Dr. Jeffrey E. L ee, Dr. Nicholas E. Papadopoulos, Dr. Merrick Ross, and Dr. Gunar Zagars.
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samples. In instan ces wh ere the initial
biopsy is inadequa te for comple te
microstaging, it should be repeated.
Clinical staging
Additional workup is based on the
rPs11lts of microstal!in!!. Ihis should

the standard of care for patients
presenting with clinically localized
melanoma. According to Dr. Lee,
'We believe th at all patien ts with at
least interme dia te-thickness lesions
with clinically localized disease should
be offered lymphatic mapping as part
of initial treatment."
In this Qiocedure, the sentine]Jymph

regional nodal recurren ce. According
to Dr. Eton , this list may be expanded
intuitively to include patients with intran sit disease, although data are few
for this subgroup of patients as they
are too small a group to study in a
randomized trial. This treatment has
been shown in phase III trials to
consistentl,r_improve median time to

Radiotherapy
Radiotherapy has been traditionally considered to be of limited use in
the treatment of melanoma because
this type of cancer is often radioresistant. However, according to Dr.
Zagars, new strategies have made
radiotherapy a useful adjunct, and it
should be considered where there are
factors such as multiple lymph node
metastases or extranodal extension
that portend a risk for recurrence.
Currently at M. D. Anderson, one
such strategy consists of high-dose
treatments administered over a
shorter period of time than conventional radiotherapy. External beam
radiation is given directly to the site
as a few (5 or 6) treatments in large
doses (600 cGy) . Therapy is given
over a period of 10 to 14 days, for
a total of approximately 3000 cGy.
However, Dr. Zagars points out, "This
is a fairly high-risk treatment that
we don't recommend outside ofa
comprehensive cancer center." Where
this is not possible, he recommends
conventionally delivered radiotherapy.
Radiation therapy in combination
with chemotherapy (chemoradiation)
is also under investigation in the
treatment of patients at high risk
for melanoma.
Treatment of Metastases
Isolated hyperthermic limb perfusion

This is a technique for controlling
melanoma that has spread to involve
dermis or subcutaneous tissue of an
affected limb between the primary
site and the closest lymph node basin
(in-transit metastases). The artery and
vein are cannulate d and placed on
bypass to isolate the blood flow of
the limb from general circulation,
allowing prolonged perfusion of the
area with high doses of chemotherapeutic agents. Generally, the cytotoxic
agent melphalan is used, and the limb
is heated to a temperature of 40°C.
•

I

l _

. .... "JII.K

T""'\

include a thorough history and
physical examination for all patients.
Patients with in situ lesions require
no specific additional workup before
undergoing local excision, unless
such is indicated by other factors in
individual cases. Patients with clinically localized invasive melanomas
should have chest x-rays and measurement ofLDH levels along with any
other preoperative studies indica te d
by the individual situation, while
those with mo re advanced disease
sh ould h ave additional studies to
identify po tential metastases, including CT scans of the involved areas.
MRI study of the brain is appropriate
in patients who present with metastatic disease to identify potentially
treatable lesions, and bone scans
should be reserved for patients who
have symptoms of bone metastases.
Primary Treatment
The primary treatment for clinically localized malignant melanomas
is surgical removal of the lesion by
wide local excision.
Clark's level I lesions (in situ) that
are removed by local excision with
margins of0.5-1.0 cm require no
additional investigation or treatment,
nor do Clark's level II or III lesions
thinner than 1.0 mm if a clear surgical
margin of 1 cm or more is achieved.
For lesions thicker than 1.0 mm,
as well as for those that are ulcerated
or extend into the reticular dermis, a
surgical margin of 2 cm is recommended, and lymph node studies are
indicated. In centers where it is available, intraoperative lymphatic mapping
with sentinel node biopsy is recommended. This is a low-risk surgical
procedure with minimal associated
morbidity, and it may be done as day
surgery, preferably at the same time as
the wide local incision. The information obtained is the most accurate
indicator in determining lymph node
status, disease stage, and underlying
patient prognosis and therefore
entirely appropriate to use as a basis
for recommending further treatment.
At M. D. Anderson , it is considered

node in the lymphatic drainage b~in is
identified and removed for histologic
study. Dr. Ross recommends deferdng
further surgery to await results of
pathologic evaluation of sentinel node
biopsy by permanent serial section
rather than by frozen section.
When the sentinel node is found to
contain metastatic melanoma, lymph
node dissection should be performed
to remove th e remaining n odes in that
basin , and adjuvant therapy can be
offered. Where no disease is found in
the sentinel node, removal of additional n odes is not necessary.
It should be noted that precise
evaluation of sentinel nodes by this
method is best performed at the same
time as wide local excision; in fact, if
wide excision is performed without
sentiliel node biopsy, lymph node
mapping may not be accurate later.
Where lymphatic mapping is not
available or cannot be achieved,
elective lymph node dissection
may be indicated instead.
Lymphoscintigraphy is recommended prior to surgery in cases
whe~e the lymphatic drainage basin is
not obvious (i .e. , tumor locations that
may drain to more than one lymph
node basin, including many trunk
and head and neck lesions) .
Adjuvant Therapy
Adjuvant therapy should be considered following surgical resection of
melanoma for patients considered to be
at high risk for recurrence as evidenced
by lymph node involvement, especially
when there is extranodal or extracapsular extension, by matted lymph nodes,
or by the surgeon's prerogative. There
are several modalities to consider,
but this represents one of the most
challenging areas of current clinical
cancer research.
Systemic therapies
The FDA has approved adjuvant
high-dose interferon alpha-2b (Intron®
A, Schering Inc.) for a year for
patients at high risk for recurrence
after resection of a deep primary
lesion (over 4 mm in depth) or

progressio~, albeit in a time frame
e quivalent to approximately the
a mo u nt of time on the ra py. The
impact on overall survival rate is
modest and can potentially be
achieved either by immediate treatment in a proactive adjuvant setting
or by later combining Intron A with
other agents in the subset of patients
who have evidence of disease progressio n . Although interferon alpha-2b,
a cloned biologic agent, is a naturally
occurring molecule produced in
humans in response to infectio ns
and other processes, it should be
noted that this regimen uses high
doses and is associated with significant but reversible toxicity. However,
there are patients who can tolerate
this treatment quite well, especially
younger patients.
All of our experts agree that
enrollment in a clinical trial should
be strongly considered for these
patients, as promising trends are
being noted in current investigations.
Biochemotherapy, an aggressive
inpatient program that combines
biologic (interferon alpha-2b and
interleukin-2) and cytotoxic agents,
has prove n efficacy in stage IV disease
and is now under investigation for
use in less advanced disease. Other
promising areas of investigation
include passive and active immunotherapy as well as adoptive cellular
immunotherapy and cytokine programs. These continue to be developed as each new insight emerges in
the field of molecular immunology.
It is hoped over time to harness,
augment, or replace natural host
defenses using a "cocktail" of these
ever more refined products. Finally,
as genomic and proteomic technologies are developed, they will allow
precise characterization of individual
patients' tumors in correlation with
clinical course. In turn, drugs designed
to address specific critical genetic
defects and with considerably reduced
toxicity can be developed. [See the May
2000 issue of On co Log for more information about current investigations in
melanoma treatment.]

An experimental protocol at M. D.
Anderson is currently evaluating
improved respo n ses with the addition
of tumor necrosis factor. According
to Dr. Ross, isolated hyperthermic
limb perfusion is frequently very
effective and represents an important
option for treatment of this difficult
category of melanoma. This procedure
is, however, a major operation with
significant morbidity, best performed
a t a sp ecialized cancer center.
Intra-arterial chemotherapy and
intrahepatic chemoembolization
These are treatmen t modalities
that may be considered for the
treatment of symptomatic metastases
and, like hyperthermic limb perfusion, are best performed at a center
experienced in those procedures.
Brain metastases
Melanoma brain metastases are
resistant to most systemic treatment
regimens (excepting the nitrosoureas
and possibly also temozolomide, a
metabolite of dacarbazine (DTIC)),
including biochemotherapy. Hence,
melanoma metastatic to the brain is
treated as a wholly separate disease
process, and surgery for single or
symptomatic metastases, radiosurgery
for fairly small metastases (3 cm or less
but still detectable by CT scan), and
whole-brain radiation therapy are
employed. Stereotactic radiotherapy
is used to focus high-dose treatment
on a very precise area. In effect, this
"radiosurgery" can target and destroy
a lesion. Dr. Zagars recommends this
for instances where lesions are few
and small; this technique is rarely
employed for more than two lesions.
Stereotactic therapy may be used in
conjunction with whole-brain irradiation to boost its efficacy. Studies are
ongoing to explore the use of chemotherapy as a "radiosensitizer" to
improve clinical results without
causing severe toxic effects.
(Continued on next page)

(Continued from previous page)
Follow-up
Our expe rts recomme nd posttreatm ent surveilla n ce fo r the purpose of
early de tection of recurre n ce or a
second p rimary me la n o ma. An
additional conside ra tion fo r the
p rimar y care physician is ide ntification of o ther fa mily me mbe rs at ri sk.
For all pa tie nts, follow-up visits sho uld
be conducted as shown in the guideline o r mo re freque ntly a t the discretio n of the physicia n . At M . D.
Ande rson , pa tie nts receive fo llow-up
care a t three-month inte rvals for at
least the fi rst two years afte r regio nal
recurre n ce, since this is th e period
m ost likely to be associated wi th
progressio n of disease. Subseque nt
follow-up visits in th e disease-free
setting can th e n be at p rogressively
lon ger inte r vals. Pa tie n ts are carefu lly
educated regarding sign s a nd symptom s of recurre n ce. Du ring treatm e nt, patie nt fo ll ow-up visits occu r
a t sh o r ter inte r vals with freque n t restaging (as sh o rt as six-week intervals
in the stage IV setting) to m o ni tor
respo n se.

Authors' Perspectives
The first biopsy is a critical event in
the cou rse of a pa ti e nt's treatm e n t fo r
m alignan t melan oma. Dr. Lee emphasizes that accurate histopatho logy is
ver y importan t in evaluation of
patien ts wi th me lan o ma a nd for
treatmen t strategy decisions as we ll
as in counseling patients about the risk
of recurrence. It is therefore important that the in itial biopsy of a suspected melanoma be performed with
that in m ind. Full-thickness biopsies
shou ld be evaluated by an experienced
dermatopathologist. Attempts at wide
surgical excision at the time o f biopsy
are discouraged, as these may compromise later necessary lymph atic stud;.

trals

Clinical
are currently the
best option tpr adjuvant therapy
for malign~ melanoma. Al tho ugh
advan ced m lan o ma h as bee n
trad itio n ally considered a resistant
solid tumo r, r. Eto n notes tha t
increasingly req ue nt respo nses to
combined od ali ty the rapy are being
seen . This m a ns continually improving palliativ resul ts in at
least 50% of p a tie n ts. So me of these
program s ar being aggressively
develop ed i the earlie r stage 1-111
settings to d crease the freque n cy
of disease re u rre n ce in pa tie n ts and
to improve s r vival time. All of o ur
expe r ts agre tha t wh ere sh own in
the guideli n as an op tio n, refe r ral
to clinical tr~lals often re p rese n ts
the best ch o ce for pa tie n ts.
Find m o r info rma ti o n abou t
and curre n t p rotocols
. D. And erson at http://
-son. org/research/.
ost cancers, there is a
strong case ~or early detection. Al l
of ou r exp e ts agree th at th e outcom es in th i disease are largely
d ependent~on disease stage at
p resen tatio . According to the
Natio nal Co preh e n sive Can cer
Network (N CN), the lo ng-term
su rvival rate exceeds 90% wh e n
tu mors are 1.5 m m in thickness.
As tu mor th ckness increases, so
does the lik .(ih ood of regional nodal
involvemen in which surviva l rates
are "roughl h alved"; and wh en
distant me tases are present,
long-term s rvival rates are less
than 10%. I the case of melanoma,
n is feasible and ecost melanomas may b
simple but thorough
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